Brind.
  1. Iovance Biotherapeutics saw revenue gains from its product lifileucel (Amtagvi), but the company faced market underperformance and corporate leadership changes.

Roche was appointed as the new CFO of Iovance Biotherapeutics.

2 reports, 2 independent Updated Aug 1
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Roche was appointed as the new CFO of Iovance Biotherapeutics.

Who's involved

What this event is mainly about
Hoffmann-La RocheIovance Biotherapeutics

Keep exploring

Part of

Iovance Biotherapeutics saw revenue gains from its product lifileucel (Amtagvi), but the company faced market underperformance and corporate leadership changes. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Iovance Biotherapeutics (IOVA) Names Corleen Roche as New CFO Iovance Biotherapeutics recently announced key executive changes alongside positive clinical study results for Amtagvi, which have likely
  • GlobeNewswireIovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnolog